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Abstract
Protective effects of prostacyclin (PC) or its stable analog beraprost against agonist-induced lung 
vascular inflammation have been associated with elevation of intracellular cAMP and Rac GTPase 
signaling which inhibited the RhoA GTPase-dependent pathway of endothelial barrier 
dysfunction. This study investigated a distinct mechanism of PC-stimulated lung vascular 
endothelial (EC) barrier recovery and resolution of LPS-induced inflammation mediated by small 
GTPase Rap1. Efficient barrier recovery was observed in LPS-challenged pulmonary EC after 
prostacyslin administration even after 15 hrs of initial inflammatory insult and was accompanied 
by the significant attenuation of p38 MAP kinase and NFkB signaling and decreased production of 
IL-8 and soluble ICAM1. These effects were reproduced in cells post-treated with 8CPT, a small 
molecule activator of Rap1-specific nucleotide exchange factor Epac. By contrast, pharmacologic 
Epac inhibitor, Rap1 knockdown, or knockdown of cell junction-associated Rap1 effector afadin 
attenuated EC recovery caused by PC or 8CPT post-treatment. The key role of Rap1 in lung 
barrier restoration was further confirmed in the murine model of LPS-induced acute lung injury. 
Lung injury was monitored by measurements of bronchoalveolar lavage protein content, cell 
count, and Evans blue extravasation and live imaging of vascular leak over 6 days using a 
fluorescent tracer. The data showed significant acceleration of lung recovery by PC and 8CPT 
post-treatment, which was abrogated in Rap1a−/− mice. These results suggest that post-treatment 
with PC triggers the Epac/Rap1/afadin-dependent mechanism of endothelial barrier restoration 
and downregulation of p38MAPK and NFkB inflammatory cascades, altogether leading to 
accelerated lung recovery.
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1. INTRODUCTION
Acute respiratory distress syndrome (ARDS) represents a spectrum of common syndromes 
in response to a variety of infectious and non-infectious insults. Until now there remain few 
effective therapeutic approaches towards for this devastating illness, mortality rates 
(30-40%) remain unacceptably high [1,2], and novel treatments aimed at reducing vascular 
leak and acute inflammation in lung injury have yet to be developed. Despite the recent 
progress towards understanding the basis of increased EC permeability (see [3,4] for 
review), molecular events stimulating EC barrier restoration in the course of ALI remain 
poorly understood.
Prostaglandins represent an important group of lipid mediators with barrier-protective 
potential towards the vascular endothelium [5]. While prostaglandin E2 (PGE2) and 
thromboxanes appear to participate in the propagation of inflammation [6,7], other 
prostaglandins such as PGE1 and prostacyclin (PC) exhibit potent protective effects in 
ischemia-reperfusion [8] and ventilator induced lung injury [9]. The beneficial effects of 
prostaglandins extend beyond their vasodilating effects and regulation of local circulation 
and involve direct protective effects on the vascular endothelium [5,10,11]. Protective 
effects of PC and its synthetic analogs, iloprost and beraprost, have been characterized by 
several groups [5,11-14].
Elevation of intracellular cyclic AMP (cAMP) levels is a major cellular response to PC. In 
pulmonary vascular endothelia, PC-induced elevation of cAMP at submembrane 
compartment promotes enhancement of the EC barrier [5,11,15]. Barrier-protective effects 
of cAMP-elevating agents on EC monolayers have been previously associated with an 
inhibitory role of cAMP-activated protein kinase A towards an agonist-induced EC 
contractile response mediated by RhoGTPase and myosin light chain kinase and leading to 
EC barrier disruption [16-19]. An alternate, PKA-independent pathway of EC barrier 
enhancement, involves cAMP-activated guanine nucleotide exchange factor (GEF) Epac1 
and its target Rap1 GTPase, which strengthens the endothelial barrier by de novo formation 
or enhancing the existing intercellular adhesive complexes via its cell adhesion effector 
afadin [20,21].
It is also important to note that the intracellular location of cAMP pool critically determines 
its physiological outcome. While PC-induced generation of cyclic AMP in the subplasma 
membrane compartment activates PKA and Epac signaling leading to tightening of cell 
adhesions, strengthening of cortical actin cytoskeleton, reduction of actomyosin contraction, 
and enhancement of EC barrier described above, expansion of cAMP from sub-membrane 
compartment to the cytosolic compartment caused by soluble adenylate cyclases from 
pathogenic bacteria disrupts the endothelial barrier through PKA-mediated disassembly of 
microtubules [22,23].
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Afadin is a scaffold protein activated by small GTPase Rap1, which promotes the assembly 
of cadherin-based adherens junctions [24,25], but also interacts with tight junction protein 
ZO-1 and adherens junction proteins α-catenin and p120-catenin. Rap1-induced p120-
catenin association with afadin promotes p120-catenin localization to the adherens junctions 
and enhances AJ – TJ interactions in endothelial cells [26].
In addition, Rap1 activates Rac-specific guanine nucleotide exchange factors Tiam1 and 
Vav2 and promotes the parallel pathway of EC barrier by stimulating Rac GTPase signaling 
[11,27]. In contrast to the well recognized role of Rac1 signaling in endothelial barrier 
enhancement and the negative Rac-Rho crosstalk mechanism of EC barrier protection in the 
models of agonist-induced permeability, a role of Rap1 signaling in EC barrier restoration 
during septic inflammation and the link between cytoskeletal remodeling and modulation of 
inflammatory signaling in EC remains completely unexplored.
Many experimental models for screening novel protective compounds utilize preventive or 
concurrent treatment during ALI induction, while post-treatment remains the more clinically 
relevant intervention. These differences in application of protective agonists may have a 
dramatic impact on the outcome and interpretation of molecular mechanisms contributing to 
the downregulation or resolution of ongoing injury in contrast to preventing the initial 
disruptive signaling leading to ALI.
In this study we used biochemical, molecular, and functional approaches to characterize 
effects of PC post-treatment on the in vitro and in vivo models of LPS-induced lung injury. 
Using pharmacologic inhibitors and activators of Epac, genetic model of Rap1a knockout 
mice and Rap1 knockdown in vitro, we investigated a role of Epac-Rap1 mechanism in the 
modulation of LPS-induced ALI by PC post-treatment.
2. MATERIALS AND METHODS
2.1. Cell culture and reagents
Human pulmonary artery endothelial cells (HPAEC) and cell culture medium were obtained 
from Lonza Inc (Allendale, NJ), and used at passages 5-8. Unless specified, biochemical 
reagents were obtained from Sigma (St. Louis, MO). PC and beraprost were obtained from 
Cayman (Ann Arbor, MI); 8-(4-Chlorophenylthio)-2′-O-methyl-adenosine-3′,5′-cyclic 
monophosphate (8CPT) and Epac cell permeable inhibitor ESI-09 were purchased from 
Calbiochem (La Jolla, CA). Phospho-p38, IκBα, NFκB, β-actin antibodies were obtained 
from Cell Signaling (Beverly, MA); Rap1, phospho-VE-cadherin, VE-cadherin, ICAM1, 
and VCAM1 from Santa Cruz Biotechnology (Santa Cruz, CA). All reagents for 
immunofluorescence were purchased from Molecular Probes (Eugene, OR).
2.2. Measurement of endothelial permeability
The cellular barrier properties were analyzed by measurements of transendothelial electrical 
resistance (TER) across confluent human pulmonary artery endothelial monolayers using an 
electrical cell-substrate impedance sensing system (Applied Biophysics, Troy, NY) as 
previously described [28,29].
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2.3. Neutrophil migration and adhesion assays
Neutrophil chemotaxis was measured in a 96-well chemotaxis chamber (Neuroprobe, 
Gaithersburg, MD) as described previously [30]. Briefly, freshly isolated neutrophils were 
placed in a 96-well chemotaxis chamber and incubated with 200 μl of preconditioned culture 
media, which was collected from stimulated EC cultures. Preliminary experiments have 
established that the number of cells (4 × 104 cells) used allow the optimal cell migration 
without clogging the pores of transwell filter of the upper chamber. Data were expressed as 
percent of cell migration. PMN adhesion to the EC was assessed by adding the neutrophils 
freshly isolated from healthy donors to the EC monolayers grown in the 6-well plates. 
Neutrophil adhesion on HPAEC was assessed as described previously [31]. Neutrophil 
adhesion data were expressed as percentage of adhesion for all treated groups.
2.4. siRNA transfection
To reduce the content of endogenous Rap1 or afadin, cells were treated with gene-specific 
siRNA duplexes [26,32]. Pre-designed standard purity siRNA sets (Homo sapiens) were 
ordered from Dharmacon (Lafayette, CO), and transfection of EC with siRNA was 
performed as previously described [33]. After 48-72 hrs of transfection, cells were used for 
experiments or harvested for western blot verification of specific protein depletion. 
Nonspecific, non-targeting siRNA (Dharmacon, Lafayette, CO) was used as a control 
treatment.
2.5. Immunofluorescence
Endothelial monolayers plated on glass cover slips were subjected to immunofluorescence 
staining as described previously [34]. Slides were analyzed using a Nikon video imaging 
system (Nikon Instech Co., Tokyo, Japan). Images were processed with Image J software 
(National Institute of Health, Washington, USA) and Adobe Photoshop 7.0 (Adobe Systems, 
San Jose, CA) software. Quantitative analysis of paracellular gap formation was performed 
as previously described [29,35,36]. The 16-bit images were analyzed using MetaVue 4.6 
software (Universal Imaging, Downington, PA). The gap formation was expressed as a ratio 
of the gap area to the area of the whole image. The values were statistically processed using 
Sigma Plot 7.1 (SPSS Science, Chicago, IL) software. For each experimental condition at 
least 10 microscopic fields in each independent experiment were analyzed.
2.6. Differential protein fractionation and immunoblotting
Confluent HPAEC were stimulated with LPS with or without PC and nuclear fraction was 
isolated using S-PEK kit (EMD Chemicals, Gibbstown, NJ). Immunoblotting detection of 
proteins of interest was performed as described previously [37]. Protein extracts from mouse 
lungs or EC were separated by SDS-PAGE, transferred to polyvinylidene difluoride 
membranes, and the membranes were incubated with specific antibodies of interest. Equal 
protein loading was verified by probing for β-actin. Immunoreactive proteins were detected 
with the enhanced chemiluminescent detection system according to the manufacturer’s 
protocol (Amersham, Little Chalfont, UK).
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2.7. Measurement of cytokines and chemokines
The concentrations of KC in mouse bronchoalveolar lavage (BAL) fluid samples were 
measured using a Mouse Cytokine Multiplex Panel according to the manufacturer’s protocol 
(Millipore, Billerica, MA). For interleukin-8 (IL-8) and soluble ICAM1 (sICAM1) 
measurements in preconditioned medium of human pulmonary EC cultures, supernatants 
from treated EC were collected and centrifuged to remove debris. IL-8 and sICAM1 levels 
were determined by ELISA (R&D Systems, Minneapolis, MN) following manufacturer’s 
protocol. Absorbance was read at 450 nm within 30 min in microplate reader (Thermomax; 
Molecular Devices, Menlo Park, CA).
2.8. Animal studies
All animal care and treatment procedures were approved by the University of Chicago 
Institutional Animal Care and Use Committee. Animals were handled according to the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. Rap1a−/− 
mice have been described elsewhere [38,39]. C57BL/6J mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). Bacterial lipopolysaccharide (LPS, 0.63 mg/kg body wt; 
Escherichia coli O55:B5) or sterile water was injected intratracheally in a small volume 
(20–30 μl) using a 20-gauge catheter (Exelint International, Los Angeles, CA). Beraprost 
(20 μg/kg), 8CPT (20 μM/kg) or sterile saline solution was administrated 5 hrs after LPS 
instillation by intravenous injection in the external jugular vein. These doses have been 
selected based on results of pilot studies, which showed potent anti-inflammatory and barrier 
protective effects of PC and 8CPT without visible adverse effects on experimental animals. 
After 18 hours of LPS challenge, animals were sacrificed by exsanguination under 
anesthesia. BAL was performed using 1 ml of sterile Hanks balanced salt buffer and 
measurements of cell count and protein concentration were conducted as previously 
described [40]. For analysis of LPS-induced lung vascular leak, Evans blue dye (30 ml/kg) 
was injected into the external jugular vein 2 hrs before termination of the experiment. 
Measurement of Evans blue accumulation in the lung tissue was performed by 
spectrofluorimetric analysis of lung tissue lysates according to the protocol described 
previously [41,42]. For histological assessment of lung injury, the lungs were harvested 
without lavage collection and fixed in 10% formaldehyde. After fixation, the lungs were 
embedded in paraffin, cut into 5-μm sections, and stained with hematoxylin and eosin. 
Sections were evaluated at 40x magnification.
2.9. In vivo optical imaging
Mice were injected with 100 μl of 2 nmol Angiosense 680 EX (a vascular fluorescent blood 
pool imaging agent purchased from PerkinElmer, Inc., Boston, MA; cat# NEV10054EX), 
intravenously via tail vein. After 24 hours, fluorescent optical imaging was performed in the 
Integrated Small Animal Imaging Research Resource (iSAIRR) at the University of Chicago 
using Xenogen IVIS 200 Spectrum (Caliper Life Sciences. Alameda, CA). Mice were 
exposed to isoflurane anesthesia with O2 through the gas anesthesia manifold and placed on 
the imaging stage. Acquisition and image analysis were performed with Living Image 4.3.1 
Software.
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2.10. Statistical analysis
Results are expressed as means ±SD of three to eight independent experiments. Stimulated 
samples were compared to controls by unpaired Student’s t-test. For multiple-group 
comparisons, one-way ANOVA and Tukey’s post hoc multiple-comparison test were used. 
P<0.05 was considered statistically significant.
3. RESULTS
3.1. Effects of PC post-treatment on LPS-induced endothelial hyperpermeability and 
disruption of monolayer integrity
Treatment of ongoing inflammation with protective compounds represents a more clinically 
relevant scenario of pharmacological intervention. Therefore, in the following studies we 
evaluated the effects of PC post-treatment in the model of EC barrier dysfunction and 
inflammation induced by LPS. PC added after 30 min, 2 hrs, 5 hrs or 15 hrs of LPS 
stimulation exhibited potent barrier protective effects reflected by pronounced and sustained 
elevation of transendothelial electrical resistance (TER) (Figure 1A).
Because previous studies by our group described a role for small GTPase Rap1 activated by 
Rap1-specific guanine nucleotide exchange factor Epac in the direct effect of PC on EC 
barrier [11], we examined a role of the Epac-Rap1 pathway in barrier recovery of LPS-
challenged EC monolayers. In these experiments, LPS-challenged EC were treated with 
selective Epac activator, 8CPT, and the EC permeability response was monitored by 
measurements of TER. Post-treatment with 8CPT 30 min - 15 hrs after LPS challenge 
caused recovery of EC barrier (Figure 1B).
Recovery of LPS-induced EC barrier failure by PC post-treatment monitored by TER 
measurements was further linked to cytoskeletal changes. EC stimulation with LPS for 5 hrs 
caused the formation of actin stress fibers (Figure 1C), disruption of the continuous line of 
VE-cadherin positive paracellular adherens junctions (Figure 1D) and the appearance of 
paracellular gaps reflecting compromised EC barrier. Remarkably, the addition of PC after 5 
hrs of LPS treatment caused reduction of stress fibers and restoration of the continuous 
adherens junction pattern accompanied by the resealing of paracellular gaps observed 30 
min – 2 hrs after PC or 8CPT post-tretament (Figure 1CD). The bar graph represents results 
of quantitative analysis of PC and 8CPT post-treatment effects on LPS-induced gap 
formation.
3.2. PC post-treatment suppresses LPS-induced EC inflammatory activation
We investigated the effects of PC and 8CPT post-treatment on LPS-induced activation of 
inflammatory signaling. EC exposure to LPS for 2.5 hrs caused pronounced 
phosphorylation/activation of p38 MAP kinase, degradation of the IκBα inhibitory subunit 
(Figure 2A), and nuclear translocation of NFκB (Figure 2B) required for inflammatory gene 
expression. These effects were suppressed by post-treatment with PC or 8CPT 30 min after 
LPS challenge.
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At later time points (24 hrs), LPS increased expression of ICAM1 and VCAM1, the 
adhesion molecules involved in EC-neutrophil interaction, while post-treatment with PC 5 
hrs after LPS challenge abolished these effects (Figure 2C). Similar effects were observed in 
experiments with 8CPT post-treatment.
In complementary studies we measured the production of soluble ICAM1 (sICAM1) and 
neutrophil chemoattractant cytokine IL-8. The addition of PC 5 hrs after LPS challenge 
markedly attenuated sICAM1 and IL-8 production by pulmonary EC detected in the 
preconditioned culture medium 24 hrs after LPS addition (Figure 2D). Similar effects were 
observed in cells post-treated with 8CPT.
Activation of the vascular endothelium by inflammatory agents stimulates neutrophil 
adhesion to the EC lining the vascular luminal surface and following neutrophil 
transmigration through the EC monolayer leading to neutrophil recruitment to the inflamed 
lung parenchyma. Effects of PC post-treatment of LPS-induced lung dysfunction were 
evaluated in cell functional assays. Exposure of pulmonary EC to LPS (24 hrs) stimulated 
neutrophil migration and adhesion. Importantly, neutrophil migration stimulated by 
preconditioned medium from LPS-stimulated EC (Figure 2E) and EC-neutrophil interactions 
(Figure 2F) were significantly attenuated by post-treatment with PC or 8CPT 5 hrs after LPS 
addition.
3.3. Rap1 pathway is involved in EC recovery upon PC post-treatment
Our recent study demonstrated a role of Rap1 signaling during EC barrier restoration after 
thrombin-induced increase in EC permeability [32]. The following experiments tested 
involvement of the Rap1 mechanism in suppression of inflammatory signaling and barrier 
restoration in LPS-challenged pulmonary EC caused by PC post-treatment.
Inhibition of PC-induced Rap1 activation was first achieved by cell pretreatment with the 
Epac1 inhibitor, which blocked PC-induced activation of the Epac1-Rap1 pathway. Such 
inhibition of Epac1-Rap1 abolished the anti-inflammatory effect by PC reflected by 
attenuation of LPS-induced IkBa degradation (Figure 3A) and ICAM1 and VCAM1 
expression (Figure 3B). EC incubation with Epac1 inhibitor did not significantly affect LPS-
induced degradation of IkBa inhibitory subunit and increase in ICAM1 and VCAM1 
expression. Inhibition of Epac1 also prevented the restoration of the EC barrier caused by 
PC post-treatment of LPS-challenged EC (Figure 3C).
The role of Rap1 in EC barrier restoration induced by PC post-treatment was further 
assessed in experiments with siRNA-mediated Rap1 knockdown. Increased VE-cadherin 
peripheral staining caused by PC post-treatment (1 hr after LPS), which reflects restoration 
of cell-cell adhesions in LPS-treated cells (Figure 4A, left panel) was attenuated in Rap1-
depleted lung EC monolayers, which also exhibited increased paracellular gap formation. 
(Figure 4A, right panel, shown by arrows).
VE-cadherin phosphorylation at Y731 is known to promote disassembly of the adherens 
junction complexes [43,44]. Post-treatment with PC or 8CPT (5 hrs after LPS) attenuated 
LPS-induced VE-cadherin phosphorylation at Y731, and also blocked expression of ICAM1 
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and VCAM1 (Figure 4B). Rap1 knockdown by gene-specific siRNA abolished the 
protective effects of PC and 8CPT post-treatment.
The role of the Rap1 pathway in the mediation of PC anti-inflammatory response was 
further investigated in experiments with inhibition of Rap1 cytoskeletal target afadin, 
involved in formation of cell-cell adhesive complexes [45,46]. siRNA-induced knockdown 
of afadin blocked the protective effects of PC post-treatment against LPS-induced disruption 
of VE-cadherin positive adherens junctions (Figure 5A) and inflammatory signaling 
monitored by increased ICAM1 expression (Figure 5B). These data suggest the key role of 
the Rap1-afadin axis in the mediation of PC effects on EC barrier restoration after an 
inflammatory insult. A role of the PC-Rap1 axis in tissue barrier restoration after 
inflammatory challenge was further evaluated in animal models.
3.4. Time course image analysis of PC post-treatment effects on lung recovery after LPS-
induced injury
Lung vascular leak in mice treated with LPS and the stable PC analog beraprost was 
monitored in the same animals prospectively, 1, 2, 3, and 6 days after treatment. Angiosense 
680 EX tracer was injected intravenously, and tracer accumulation in the lungs reflecting 
lung vascular barrier dysfunction and lung injury was performed in anesthetized animals 
using the non-invasive fluorescence optical imaging approach described in Methods. 
Accumulation of the fluorescent tracer reflecting lung inflammation and vascular barrier 
compromise was observed 24 hrs after LPS injection, reaching maximal levels at day 2 and 
gradually declining by day 6 (Figure 6A). Importantly, lung dysfunction was noticeably 
reduced in mice post-treated with beraprost 5 hrs after LPS challenge, and recovery of lung 
function occurred earlier than in mice without PC post-treatment. The results were supported 
by quantitative analysis of lung imaging data.
Results of live imaging studies were supported by conventional analysis of bronchalveolar 
lavage protein content and cell counts in parallel experiments. Intravenous injections of PC 
or 8CPT after 5 hours of LPS instillation significantly decreased BAL protein content and 
total cell count, in the LPS-treated mice (Figure 6B).
3.5. PC post-treatment effectively suppresses LPS-induced lung barrier dysfunction and 
inflammation in vivo
Effects of PC post-treatment on the lung vascular leak induced by LPS were further 
evaluated by measurements of Evans blue extravasation into the lung tissue. Administration 
of beraprost significantly reduced LPS-induced Evans blue accumulation in the lung 
parenchyma (Figure 7AB). In agreement with cell culture studies, beraprost post-treatment 
inhibited LPS-induced ICAM1 expression (Figure 7C) in the lung detected by western blot 
analysis of lung tissue homogenates.
3.6. Rap1 mediates improved recovery of LPS-induced lung injury caused by PC post-
treatment
Although the Rap1b genetic variant of the Rap1 protein is expressed in vascular 
endothelium at higher levels [47], the vascular endothelial barrier function is more sensitive 
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to depletion of the Rap1a variant [48,49]. The role of Rap1 in the lung recovery after 
inflammatory insult was evaluated using the genetic model of Rap1a−/− mice. First, we 
evaluated the magnitude of LPS-induced lung injury in Rap1a−/− mice. Parameters of lung 
injury in Rap1a−/− mice and matching controls were analyzed at day 1, 2, 3, 5, and 7 after 
LPS administration. In comparison to wild type controls, Rap1a−/− mice developed more 
severe lung injury in response to LPS which was reflected by measurements of protein 
content (Figure 8A) and cell counts (Figure 8B) in BAL samples from LPS-challenged wild 
type and knockout animals. Western blot analysis of lung tissue samples revealed more 
prominent ICAM1 expression in Rap1a−/− mice at day 5 after LPS challenge (Figure 8C).
The next experiments evaluated the effects of beraprost post-treatment in LPS-challenged 
control and Rap1a knockout animals. Rap1a−/− mice and matching controls were injected 
with vehicle or beraprost 5 hrs after the LPS challenge. Protective effects of PC post-
treatment against LPS-induced increases in BAL cell count and protein content observed in 
wild type controls were abolished in Rap1a−/− mice (Figure 9A).
Histological analysis of lung tissue sections stained with hematoxylin and eosin showed that 
in contrast to wild type controls, the protective effects of PC against LPS-induced alveolar 
wall thickening and increased leukocyte infiltration were diminished in the Rap1 knockout 
mice (Figure 9B). Attenuation of LPS-induced ICAM1 expression by beraprost was 
observed in wild type controls and was abolished in Rap1a−/− mice (Figure 9C). Next, 
effects of PC on LPS-induced cytokine production were tested in control and Rap1a−/− 
mice. In consistence with in vitro results, protective effect of beraprost against LPS-induced 
elevation of mouse IL-8 homologue KC was suppressed in the Rap1 knockout animals 
(Figure 9D). Taken together, these results demonstrate pronounced anti-inflammatory and 
barrier-protective effects of PC post-treatment in the animal model of LPS-induced lung 
inflammatory injury and vascular leak and emphasize a key role of Rap1 in the mediation of 
PC protective effects.
4. DISCUSSION
The main finding of this study is a role of Rap1 signaling in attenuation of ongoing lung 
inflammation and barrier dysfunction in a septic model of ALI. This is also the first 
demonstration of a dramatic improvement of EC barrier function and ongoing lung injury 
achieved by post-treatment with PC and its stable analogs.
Many models of post-treatment show a relatively short efficient therapeutic window (10-30 
min of post-treatment) effective to inactivate an injurious stimulus [50-52]. The PC 
pretreatment used in this study efficiently attenuated parameters of lung inflammation and 
accelerated EC barrier recovery even when it was administered 15 hrs after LPS challenge in 
vitro and 5 hrs after LPS challenge in vivo. In addition to analysis of BAL parameters of 
lung injury, we monitored the time course of lung vascular leak in control and PC-treated 
mice with LPS-induced ALI using a non-invasive live imaging approach. Live imaging of 
LPS-induced ALI in mice with or without PC post-treatment has been performed for the first 
time and demonstrated a significant acceleration of lung recovery by PC post-treatment. 
Tracking the time dependent changes in the same animal in the course of ALI is a powerful 
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approach aimed to diminish individual variability in the magnitude of inflammatory 
response to an intervention. This analysis was complemented by morphological and 
biochemical data and demonstrated high consistence of traditional parameters of ALI and 
live imaging data.
PC post-treatment caused remarkably rapid and potent recovery of barrier function in LPS-
challenged EC. Importantly, the recovery effect of PC was reproduced by cell pretreatment 
with a specific activator of Epac-Rap1 signaling, 8CPT. The time course of EC barrier 
recovery suggests Rap1-induced activation on vascular EC cytoskeleton and restoration of 
the cell junction barrier as a leading mechanism of EC barrier recovery caused by PC post-
treatment. Besides direct stimulation of cell junction assembly, Rap1 also promoted re-
sealing of intercellular gaps in EC monolayers stimulated with thrombin [32]. These Rap1 
effects had been associated with Rap1-dependent downregulation of Rho signaling via 
Rap1-induced Rac1-RhoA negative crosstalk. Rap1 activation in thrombin-treated 
pulmonary EC represented the mechanism of endothelial barrier auto-recovery and was 
mediated by the Rap1-specific guanine nucleotide exchange factor C3G stimulated by 
thrombin-activated Src kinase [32]. The rapid EC barrier recovery observed in this study 
suggests activation of similar mechanisms in a distinct model of EC barrier dysfunction 
caused by bacterial pathogens.
In addition to the rapid barrier recovery driven by cytoskeletal and cell junction remodeling, 
Rap1 activation by PC and 8CPT also blocked the LPS-induced inflammatory response. 
After binding to a LPS ligand, TLR4 sequentially recruits the adaptor molecules MyD88, 
IL-1R-associated kinase (IRAK), and TNF receptor-associated factor 6 (TRAF6). These 
adaptor molecules then activate MAP kinases JNK, p38, ERK1/2 and IκB, a cytoplasmic 
inhibitor of NFκB [53]. NFκB and MAP kinases mediate the LPS-induced production of 
proinflammatory cytokines. However, besides the canonical activation by the TLR4-
MyD88-IRAK-TRAF6 cascade, the p38 MAPK and NFkB activity is positively regulated 
by the small GTPase, RhoA [54,55]. In turn, inhibition of the Rho pathway attenuated the 
inflammatory and barrier disruptive EC response to bacterial pathogens [56-60]. Rap1-
mediated attenuation of Rho signaling described above in the model of thrombin-induced 
EC permeability [32], as well as downregulation of Rho-dependent lung injury by Rap1 
activity in the animal model of ventilator-induced vascular leak [14] suggest a potential 
mechanism of ALI attenuation by Rap1-Rho negative crosstalk.
This study also shows attenuation of LPS-induced ICAM1 expression by the Epac-Rap1 
mechanism. ICAM-1 is essential for stable adhesion and transmigration of leukocytes in 
most types of inflammatory processes. Blocking antibodies against ICAM-1 inhibit 
leukocyte adhesion, while the deletion of the cytoplasmic domain of ICAM-1 completely 
blocks neutrophil transmigration but not the adhesion, demonstrating the importance of 
ICAM-1–dependent signaling in mediating neutrophil transmigration [61]. Engagement of 
ICAM-1 by leukocytes results in tyrosine phosphorylation of VE-cadherin, which is 
required for efficient neutrophil TEM. Interestingly, ICAM-1 engagement leads to 
phosphorylation of VE-cadherin on tyrosines 658 and 731, which correspond to the p120-
catenin and β-catenin binding sites, respectively. Such VE-cadherin phosphorylation may be 
mediated by tyrosine kinases, Src and Pyk2 [62], or by a RhoA-dependent mechanism [63] 
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and promotes disassembly of the VE-cadherin-catenin complex and internalization of VE-
cadherin and p120-catenin leading to disassembly of adherens junctions and EC barrier 
compromise. LPS-induced disruption of adherens junctions associated with tyrosine 
phosphorylation of VE-cadherin was also observed in the current study. One consequence of 
AJ disassembly is EC barrier compromise leading to an influx of solutes and increased 
neutrophil infiltration into the lung, the process that perpetuates ongoing ALI.
Another consequence of AJ disassembly is the release of p120-catenin from cell junctions. 
In the context of LPS-induced lung inflammation, p120-catenin displacement from AJ and 
degradation may propagate inflammatory signaling. Molecular inhibition of p120-catenin 
has been associated with development of skin inflammation in p120-catenin knockout mice 
due to dysregulation of Rho signaling at cell-cell junctions [64]. Downregulation of p120-
catenin in lung EC increased the inflammatory response of LPS and the mortality in the 
animal LPS-induced sepsis model [65]. These effects were associated with p120-catenin 
modulation of lung immune function by interfering with the association of TLR4 with its 
adaptor MyD88 to block TLR4 signaling and NFκB activation in endothelial cells.
Our data show that pharmacologic inhibition of Epac, Rap1 knockdown in pulmonary EC, 
or Rap1a knockout in mice exacerbated LPS-induced lung injury. Interestingly, protective 
effects of PC and 8CPT against LPS-induced adherens junction disassembly, EC barrier 
disruption and ICAM1 expression were attenuated by the knockdown of Rap1 effector 
afadin. Afadin involvement in regulating the expression of inflammatory molecules is a 
novel finding. How may afadin be possibly involved in Rap1 anti-inflammatory signaling? 
Afadin mediates the formation of nascent adherens junctions and directly interacts with 
cadherin-associated signaling protein p120-catenin [66]. Barrier enhancing signals stimulate 
afadin interaction with AJ and TJ protein partners. p120-catenin and ZO-1 [25,26], which 
leads to the strengthening of cell-cell junctions and enhancement of EC barrier integrity. 
Based on the previous reports and current data, we suggest that, as a Rap1 effector and 
adaptor protein, afadin preserves p120-catenin localization at adhesive complexes in PC-
stimulated cells thus preventing p120-catenin from degradation and initiation of the TLR4-
MyD88-NFκB inflammatory cascade described above. These data suggest a novel role for 
Rap1 signaling in the modulation of the EC innate immune response to bacterial pathogens 
via a Rap1-afadin-dependent mechanism.
In conclusion, this is the first study demonstrating the anti-inflammatory effects of Rap1-
afadin axis in the models of LPS-induced lung injury. This study proposes a novel paradigm 
of dual Rap1-afadin-mediated anti-inflammatory mechanisms in ALI, which include: a) re-
sealing of intercellular junctions leading to enhanced EC barrier and reduced transfer of 
inflammatory molecules to the lung parenchyma; and b) inhibition of EC inflammatory 
activation (manifested by activation of cell adhesion molecules and cytokine expression). 
Beneficial effects of specific activators of Rap1 signaling on ALI recovery may have a 
substantial impact on the drug design strategies leading to the generation of more effective 
or tissue-specific Rap1 activators. As vascular barrier-protective and anti-inflammatory 
therapeutic benefits of PC are currently offset by hypotensive side effects, the potential 
utilization of Epac and Rap1 activators may overcome the disadvantages of currently 
available PC analogs. In the future, attempts to develop efficient small molecule Rap1 
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activators may provide a novel aspect of treatment of ARDS and other conditions associated 
with inflammation and vascular barrier dysfunction.
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Non-standard Abbreviations
ALI acute lung injury
BAL bronchoalveolar lavage fluid
EC endothelial cells
ECIS electrical cell-substrate impedance sensing system
HPAEC human pulmonary artery endothelial cells
LPS lipopolysaccharide
MPO myeloperoxidase
nsRNA non-specific RNA
PC prostacyclin
TER transendothelial electrical resistance
XPerT express permeability testing assay
8CPT 8-(4-Chlorophenylthio)-2′-O-methyl-adenosine-3′,5′-cyclic monophosphate
REFERENCES
1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J 
Med. 2005; 353:1685–93. [PubMed: 16236739] 
2. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000; 342:1334–
49. [PubMed: 10793167] 
3. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006; 
86:279–367. [PubMed: 16371600] 
4. Birukov KG, Zebda N, Birukova AA. Barrier enhancing signals in pulmonary edema. 
Comprehensive Physiology. 2013; 3:429–84. [PubMed: 23720293] 
5. Fukuhara S, Sakurai A, Sano H, et al. Cyclic AMP potentiates vascular endothelial cadherin-
mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling 
pathway. Mol Cell Biol. 2005; 25:136–46. [PubMed: 15601837] 
6. Goggel R, Hoffman S, Nusing R, et al. Platelet-activating factor-induced pulmonary edema is partly 
mediated by prostaglandin E(2), E-prostanoid 3-receptors, and potassium channels. Am J Respir 
Crit Care Med. 2002; 166:657–62. [PubMed: 12204861] 
7. Park GY, Christman JW. Involvement of cyclooxygenase-2 and prostaglandins in the molecular 
pathogenesis of inflammatory lung diseases. Am J Physiol Lung Cell Mol Physiol. 2006; 
290:L797–805. [PubMed: 16603593] 
8. Schutte H, Lockinger A, Seeger W, et al. Aerosolized PGE1, PGI2 and nitroprusside protect against 
vascular leakage in lung ischaemia-reperfusion. Eur Respir J. 2001; 18:15–22. [PubMed: 11510786] 
Birukova et al. Page 12
Biochim Biophys Acta. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
9. Birukova AA, Fu P, Xing J, et al. Lung endothelial barrier protection by iloprost in the 2-hit models 
of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling. Transl Res. 2010; 
155:44–54. [PubMed: 20004361] 
10. Baumer Y, Drenckhahn D, Waschke J. cAMP induced Rac 1-mediated cytoskeletal reorganization 
in microvascular endothelium. Histochem Cell Biol. 2008; 129:765–78. [PubMed: 18392843] 
11. Birukova AA, Zagranichnaya T, Alekseeva E, et al. Prostaglandins PGE2 and PGI2 promote 
endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Exp Cell 
Res. 2007; 313:2504–20. [PubMed: 17493609] 
12. Farmer PJ, Bernier SG, Lepage A, et al. Permeability of endothelial monolayers to albumin is 
increased by bradykinin and inhibited by prostaglandins. Am J Physiol Lung Cell Mol Physiol. 
2001; 280:L732–8. [PubMed: 11238014] 
13. Langeler EG, van Hinsbergh VW. Norepinephrine and iloprost improve barrier function of human 
endothelial cell monolayers: role of cAMP. Am J Physiol. 1991; 260:C1052–9. [PubMed: 
1709785] 
14. Birukova AA, Fu P, Xing J, et al. Rap1 mediates protective effects of iloprost against ventilator 
induced lung injury. J Appl Physiol. 2009; 107:1900–10. [PubMed: 19850733] 
15. Cullere X, Shaw SK, Andersson L, et al. Regulation of vascular endothelial barrier function by 
Epac, a cAMP-activated exchange factor for Rap GTPase. Blood. 2005; 105:1950–5. [PubMed: 
15374886] 
16. Yuan Y, Huang Q, Wu HM. Myosin light chain phosphorylation: modulation of basal and agonist-
stimulated venular permeability. Am J Physiol. 1997; 272:H1437–43. [PubMed: 9087622] 
17. Qiao J, Huang F, Lum H. PKA inhibits RhoA activation: a protection mechanism against 
endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2003; 284:L972–80. 
[PubMed: 12588708] 
18. Verin AD, Gilbert-McClain LI, Patterson CE, et al. Biochemical regulation of the nonmuscle 
myosin light chain kinase isoform in bovine endothelium. Am J Respir Cell Mol Biol. 1998; 
19:767–76. [PubMed: 9806741] 
19. Birukova AA, Liu F, Garcia JG, et al. Protein kinase A attenuates endothelial cell barrier 
dysfunction induced by microtubule disassembly. Am J Physiol Lung Cell Mol Physiol. 2004; 
287:L86–93. [PubMed: 15003930] 
20. Boettner B, Van Aelst L. Control of cell adhesion dynamics by Rap1 signaling. Curr Opin Cell 
Biol. 2009; 21:684–93. [PubMed: 19615876] 
21. Takai Y, Ikeda W, Ogita H, et al. The immunoglobulin-like cell adhesion molecule nectin and its 
associated protein afadin. Annu Rev Cell Dev Biol. 2008; 24:309–42. [PubMed: 18593353] 
22. Sayner SL, Alexeyev M, Dessauer CW, et al. Soluble adenylyl cyclase reveals the significance of 
cAMP compartmentation on pulmonary microvascular endothelial cell barrier. Circ Res. 2006; 
98:675–81. [PubMed: 16469954] 
23. Sayner SL. Emerging themes of cAMP regulation of the pulmonary endothelial barrier. Am J 
Physiol Lung Cell Mol Physiol. 2011; 300:L667–78. [PubMed: 21335524] 
24. Fukuyama T, Ogita H, Kawakatsu T, et al. Involvement of the c-Src-Crk-C3GRap1 signaling in the 
nectin-induced activation of Cdc42 and formation of adherens junctions. J Biol Chem. 2005; 
280:815–25. [PubMed: 15504743] 
25. Sato T, Fujita N, Yamada A, et al. Regulation of the assembly and adhesion activity of E-cadherin 
by nectin and afadin for the formation of adherens junctions in Madin-Darby canine kidney cells. J 
Biol Chem. 2006; 281:5288–99. [PubMed: 16361708] 
26. Birukova AA, Fu P, Wu T, et al. Afadin controls p120-catenin-ZO-1 interactions leading to 
endothelial barrier enhancement by oxidized phospholipids. J Cell Physiol. 2012; 227:1883–90. 
[PubMed: 21732359] 
27. Arthur WT, Quilliam LA, Cooper JA. Rap1 promotes cell spreading by localizing Rac guanine 
nucleotide exchange factors. J Cell Biol. 2004; 167:111–22. [PubMed: 15479739] 
28. Birukova AA, Adyshev D, Gorshkov B, et al. GEF-H1 is involved in agonist-induced human 
pulmonary endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2006; 
290:L540–8. [PubMed: 16257999] 
Birukova et al. Page 13
Biochim Biophys Acta. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
29. Birukova AA, Birukov KG, Smurova K, et al. Novel role of microtubules in thrombin-induced 
endothelial barrier dysfunction. FASEB J. 2004; 18:1879–90. [PubMed: 15576491] 
30. Meliton AY, Munoz NM, Meliton LN, et al. Cytosolic group IVa phospholipase A2 mediates IL-8/
CXCL8-induced transmigration of human polymorphonuclear leukocytes in vitro. Journal of 
inflammation (London, England). 2010; 7:14.
31. Meliton AY, Munoz NM, Zhu X, et al. Attenuated translocation of group IVa phospholipase A2 
and up-regulated annexin-1 synthesis by glucocorticoid blocks beta 2-integrin adhesion in 
neutrophils. J Leukoc Biol. 2008; 83:344–51. [PubMed: 17971499] 
32. Birukova AA, Tian X, Tian Y, et al. Rap-afadin axis in control of Rho signaling and endothelial 
barrier recovery. Mol Biol Cell. 2013; 24:2678–88. [PubMed: 23864716] 
33. Singleton PA, Chatchavalvanich S, Fu P, et al. Akt-mediated transactivation of the S1P1 receptor 
in caveolin-enriched microdomains regulates endothelial barrier enhancement by oxidized 
phospholipids. Circ Res. 2009; 104:978–86. [PubMed: 19286607] 
34. Birukova AA, Fu P, Xing J, et al. Mechanotransduction by GEF-H1 as a novel mechanism of 
ventilator-induced vascular endothelial permeability. Am J Physiol Lung Cell Mol Physiol. 2010; 
298:L837–48. [PubMed: 20348280] 
35. Birukova AA, Smurova K, Birukov KG, et al. Microtubule disassembly induces cytoskeletal 
remodeling and lung vascular barrier dysfunction: Role of Rho-dependent mechanisms. J Cell 
Physiol. 2004; 201:55–70. [PubMed: 15281089] 
36. Birukov KG, Jacobson JR, Flores AA, et al. Magnitude-dependent regulation of pulmonary 
endothelial cell barrier function by cyclic stretch. Am J Physiol Lung Cell Mol Physiol. 2003; 
285:L785–97. [PubMed: 12639843] 
37. Birukov KG, Bochkov VN, Birukova AA, et al. Epoxycyclopentenone-containing oxidized 
phospholipids restore endothelial barrier function via Cdc42 and Rac. Circ Res. 2004; 95:892–901. 
[PubMed: 15472119] 
38. Yan J, Li F, Ingram DA, et al. Rap1a is a key regulator of fibroblast growth factor 2-induced 
angiogenesis and together with Rap1b controls human endothelial cell functions. Mol Cell Biol. 
2008; 28:5803–10. [PubMed: 18625726] 
39. Duchniewicz M, Zemojtel T, Kolanczyk M, et al. Rap1A-deficient T and B cells show impaired 
integrin-mediated cell adhesion. Mol Cell Biol. 2006; 26:643–53. [PubMed: 16382154] 
40. Fu P, Birukova AA, Xing J, et al. Amifostine reduces lung vascular permeability via suppression 
of inflammatory signalling. Eur Respir J. 2009; 33:612–24. [PubMed: 19010997] 
41. Moitra J, Sammani S, Garcia JG. Re-evaluation of Evans Blue dye as a marker of albumin 
clearance in murine models of acute lung injury. Transl Res. 2007; 150:253–65. [PubMed: 
17900513] 
42. Nonas S, Birukova AA, Fu P, et al. Oxidized phospholipids reduce ventilator-induced vascular 
leak and inflammation in vivo. Crit Care. 2008; 12:R27. [PubMed: 18304335] 
43. Potter MD, Barbero S, Cheresh DA. Tyrosine phosphorylation of VE-cadherin prevents binding of 
p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem. 2005; 
280:31906–12. [PubMed: 16027153] 
44. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the 
control of vascular permeability. J Cell Sci. 2008; 121:2115–22. [PubMed: 18565824] 
45. Takai Y, Nakanishi H. Nectin and afadin: novel organizers of intercellular junctions. J Cell Sci. 
2003; 116:17–27. [PubMed: 12456712] 
46. Ogita H, Rikitake Y, Miyoshi J, et al. Cell adhesion molecules nectins and associating proteins: 
Implications for physiology and pathology. Proceedings of the Japan Academy. 2010; 86:621–9. 
[PubMed: 20551598] 
47. Lakshmikanthan S, Sobczak M, Chun C, et al. Rap1 promotes VEGFR2 activation and 
angiogenesis by a mechanism involving integrin alphavbeta(3). Blood. 2011; 118:2015–26. 
[PubMed: 21636859] 
48. Pannekoek WJ, van Dijk JJ, Chan OY, et al. Epac1 and PDZ-GEF cooperate in Rap1 mediated 
endothelial junction control. Cell Signal. 2011
Birukova et al. Page 14
Biochim Biophys Acta. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
49. Wittchen ES, Aghajanian A, Burridge K. Isoform-specific differences between Rap1A and Rap1B 
GTPases in the formation of endothelial cell junctions. Small GTPases. 2011; 2:65–76. [PubMed: 
21776404] 
50. Su CF, Liu DD, Kao SJ, et al. Nicotinamide abrogates acute lung injury caused by ischaemia/
reperfusion. Eur Respir J. 2007; 30:199–204. [PubMed: 17504797] 
51. Shields CJ, Delaney CP, Winter DC, et al. Induction of nitric oxide synthase is a key determinant 
of progression to pulmonary injury in experimental pancreatitis. Surgical infections. 2006; 7:501–
11. [PubMed: 17233567] 
52. Kim KS, Suh GJ, Kwon WY, et al. Antioxidant effects of selenium on lung injury in paraquat 
intoxicated rats. Clinical toxicology (Philadelphia, Pa. 2012; 50:749–53.
53. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008; 42:145–51. 
[PubMed: 18304834] 
54. Matoba K, Kawanami D, Ishizawa S, et al. Rho-kinase mediates TNF-alpha-induced MCP-1 
expression via p38 MAPK signaling pathway in mesangial cells. Biochem Biophys Res Commun. 
2010; 402:725–30. [PubMed: 20977889] 
55. Nwariaku FE, Rothenbach P, Liu Z, et al. Rho inhibition decreases TNF-induced endothelial 
MAPK activation and monolayer permeability. J Appl Physiol. 2003; 95:1889–95. [PubMed: 
12844496] 
56. Xiaolu D, Jing P, Fang H, et al. Role of p115RhoGEF in lipopolysaccharide-induced mouse brain 
microvascular endothelial barrier dysfunction. Brain Res. 2011; 1387:1–7. [PubMed: 21354111] 
57. Guo F, Zhou Z, Dou Y, et al. GEF-H1/RhoA signalling pathway mediates lipopolysaccharide-
induced intercellular adhesion molecular-1 expression in endothelial cells via activation of p38 and 
NF-kappaB. Cytokine. 2012; 57:417–28. [PubMed: 22226621] 
58. Xing J, Birukova AA. ANP attenuates inflammatory signaling and Rho pathway of lung 
endothelial permeability induced by LPS and TNFalpha. Microvasc Res. 2010; 79:26–62.
59. Kratzer E, Tian Y, Sarich N, et al. Oxidative stress contributes to lung injury and barrier 
dysfunction via microtubule destabilization. Am J Respir Cell Mol Biol. 2012; 47:688–97. 
[PubMed: 22842495] 
60. Mambetsariev I, Tian Y, Wu T, et al. Stiffness-activated GEF-H1 expression exacerbates LPS-
induced lung inflammation. PLoS One. 2014; 9:e92670. [PubMed: 24739883] 
61. Sans E, Delachanal E, Duperray A. Analysis of the roles of ICAM-1 in neutrophil transmigration 
using a reconstituted mammalian cell expression model: implication of ICAM-1 cytoplasmic 
domain and Rho-dependent signaling pathway. J Immunol. 2001; 166:544–51. [PubMed: 
11123335] 
62. Allingham MJ, van Buul JD, Burridge K. ICAM-1-mediated, Src- and Pyk2-dependent vascular 
endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration. 
J Immunol. 2007; 179:4053–64. [PubMed: 17785844] 
63. Turowski P, Martinelli R, Crawford R, et al. Phosphorylation of vascular endothelial cadherin 
controls lymphocyte emigration. J Cell Sci. 2008; 121:29–37. [PubMed: 18096689] 
64. Perez-Moreno M, Davis MA, Wong E, et al. p120-catenin mediates inflammatory responses in the 
skin. Cell. 2006; 124:631–44. [PubMed: 16469707] 
65. Wang YL, Malik AB, Sun Y, et al. Innate immune function of the adherens junction protein p120-
catenin in endothelial response to endotoxin. J Immunol. 2011; 186:3180–7. [PubMed: 21278343] 
66. Hoshino T, Sakisaka T, Baba T, et al. Regulation of E-cadherin endocytosis by nectin through 
afadin, Rap1, and p120ctn. J Biol Chem. 2005; 280:24095–103. [PubMed: 15857834] 
Birukova et al. Page 15
Biochim Biophys Acta. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Highlights
• Activation of Rap1 stimulates barrier restoration during ongoing inflammation
• Rap1 activates afadin and enhances cell junctions during lung barrier recovery
• In parallel, Rap1-afadin complex inhibits NFkB and p38 inflammatory signaling
• These effects define dual mechanism of Rap-dependent lung barrier recovery
• Pharmacologic Rap1activation may reduce lung injury and accelerate ALI 
recovery
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Figure 1. Post-treatment with prostacyclin and 8CPT recovers LPS-induced EC permeability 
and monolayer disruption
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Pulmonary EC plated on microelectrodes were stimulated with LPS (300 ng/ml), followed 
by: A – PC (200 ng/ml); or B – 8CPT (50 μM) post-treatment at different time points after 
LPS challenge, as shown by arrows. Transendothelial resistance reflecting EC monolayer 
barrier properties was monitored over 20 hours after treatments. Insets in panels A and B 
show increase in transendothelial resistance caused by treatment with PC or 8CPT alone. C 
and D: Pulmonary EC grown on glass coverslips were challenged with LPS for 5 hrs, 
followed by PC or 8CPT treatment for additional 30 min, 1 hr, or 2 hrs, as indicated. C – 
Analysis of actin cytoskeletal rearrangement was performed by immunofluorescence 
staining with Texas Red phalloidin. Paracellular gaps are marked by arrows. Bar graph 
represents quantitative analysis of paracellular gap formation in control and treated HPAEC. 
Data are expressed as mean + SD of four independent experiments; *p<0.05, vs. LPS alone. 
D – Immunofluorescence staining for VE-cadherin was performed to visualize adherens 
junctions. Insets below depict higher magnification images of VE-cadherin patterns in cell 
junction areas after different treatments.
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Figure 2. PC and 8CPT post-treatment attenuates LPS-induced EC inflammation
Pulmonary EC were challenged with LPS followed by post-treatment with PC or 8CPT. A – 
PC or 8CPT post-treatment 30 min after LPS addition followed by 2-hr incubation. 
Phosphorylation of p38 MAP kinase and degradation of IκBα was detected by 
immunoblotting with corresponding antibodies. Equal protein loading was verified by 
membrane probing with β-actin antibody. B – PC or 8CPT post-treatment 30 min after LPS 
addition followed by 2-hr incubation. NFκB nuclear translocation was assessed by 
fractionation assay. Content of NFκB in corresponding total cell lysates was analyzed to 
ensure equal loading. C – PC or 8CPT post-treatment 5 hrs after LPS addition followed by 
19-hr incubation. Protein expression of VCAM1 and ICAM1 in stimulated EC was detected 
by immunoblotting. Equal protein loading was verified by membrane probing with β-actin 
antibody. D – PC or 8CPT post-treatment 5 hrs after LPS addition followed by 19-hr 
incubation. Secretion of soluble ICAM1 and IL-8 was evaluated by ELISA assay. E and F: 
PC or 8CPT post-treatment 5 hrs after LPS addition followed by 19-hr incubation. E – 
Analysis of PMN migration stimulated by preconditioned medium from EC activated by 
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LPS with or without PC or 8CPT post-treatment. F – Analysis of PMN adhesion to EC 
activated by LPS with or without PC or 8CPT post-treatment. Data are expressed as mean + 
SD of four independent experiments; *p<0.05, vs. LPS alone.
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Figure 3. Epac inhibitor abolishes protective effects of PC and 8CPT post-treatment on LPS-
induced EC inflammation and hyperpermeability
Pulmonary EC were challenged with LPS followed by post-treatment with vehicle or PC 
with or without Epac inhibitor (50 μM). A – PC and Epac inhibitor were added 30 min after 
LPS challenge and cells were incubated for additional 2 hrs. IκBα degradation was 
evaluated by immunoblotting of total cell lysates. B – PC and Epac inhibitor were added 5 
hrs after LPS challenge and cells were incubated for additional 19 hrs. Expression of 
ICAM1 and VCAM1 was detected by immunoblotting with corresponding antibodies. Equal 
protein loading was verified by probing with β-actin antibody. C – Pulmonary EC were 
challenged with LPS with or without post-treatment with PC, with or without Epac inhibitor 
at the times indicated by arrows, and TER was measured over 20 hrs.
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Figure 4. Rap1 knockdown attenuates PC-induced EC monolayer recovery and attenuation of 
inflammation caused by LPS
A – EC plated on coverslips were transfected with Rap1-specific siRNA or non-specific 
RNA 48 hrs prior to LPS treatment followed by PC post-treatment (5 hrs after LPS) and 
additional 1-hr incubation. Cytoskeletal remodeling was assessed by immunofluorescence 
staining for F-actin with Texas Red phalloidin. VE-cadherin was detected by staining with 
VE-cadherin antibody. Shown are merged images of F-actin (red) and VE-cadherin (green) 
staining. Arrows indicate intercellular gaps. Results are representative of three independent 
experiments. B – EC were transfected with Rap1-specific siRNA or non-specific RNA 48 
hrs prior to LPS treatment followed by PC or 8CPT post-treatment (5 hrs after LPS) and 
additional 19-hr incubation. VE-cadherin phosphorylation and expression of ICAM1 and 
VCAM1 was detected by immunoblotting with corresponding antibodies. Equal protein 
loading was verified by membrane probing with β-actin antibody. Depletion of Rap1 was 
confirmed by membrane probing with Rap1 antibody.
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Figure 5. Afadin knockdown attenuates protective effects of PC post-treatment on EC 
monolayer recovery and attenuation of inflammation caused by LPS
A – EC plated on coverslips were transfected with afadin-specific siRNA or non-specific 
RNA 72 hrs prior to LPS treatment followed by PC post-treatment (5 hrs after LPS) and 
additional 1-hr incubation. VE-cadherin was detected by staining with VE-cadherin 
antibody. Arrows show sites of VE-cadherin disappearance from cell junctions. Results are 
representative of three independent experiments. B – EC were transfected with afadin-
specific siRNA or non-specific RNA 72 hrs prior to LPS treatment followed by PC or 8CPT 
post-treatment (5 hrs after LPS) and additional 19-hr incubation. Expression of ICAM1 and 
VCAM1 in control and afadin-depleted EC was detected by immunoblotting with 
corresponding antibodies. Equal protein loading was verified by membrane probing with β-
actin antibody. Depletion of afadin was confirmed by membrane probing with afadin 
antibody.
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Figure 6. Post-treatment with beraprost attenuates LPS-induced lung injury and barrier 
dysfunction
A – Live imaging analysis of lung vascular barrier dysfunction after LPS intratracheal 
injection with and without beraprost post treatment (i.v., 5 hrs after LPS). LPS-induced 
accumulation of fluorescent Angiosense 680 EX imaging agent in the lungs of same animals 
was detected by Xenogen IVIS 200 Spectrum imaging system after 1, 2, 3 and 6 days after 
LPS challenge as described in Methods and presented in arbitrary colors. Bar graph 
represents quantitative analysis of imaging data. B - Beraprost or 8CPT injection (i.v.) was 
performed 5 hrs after LPS administration (i.t.). After 24 hrs of LPS challenge mice were 
sacrificed, BAL collection was performed, and measurements of protein concentration and 
total cell count were performed in BAL samples obtained from control and experimental 
groups. Data are expressed as mean + SD of four independent experiments; n=6-10 per 
condition; *p<0.05 vs. LPS alone.
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Figure 7. Post-treatment with beraprost attenuates LPS-induced lung vascular leak and 
inflammation
Beraprost injection (i.v.) was performed 5 hrs after i.t. LPS administration. The experiment 
was terminated after 24 hrs of LPS challenge. A – Evans blue dye (30 ml/kg, i/v) was 
injected 2 hr before termination of the experiment. Photographs depict lung vascular 
permeability was assessed by Evans blue accumulation in the lung tissue. B – Quantitative 
analysis of Evans blue labeled albumin extravasation was performed by spectrophotometric 
analysis of Evans blue extracted from the lung tissue samples; n=4 per condition; *p<0.05. 
C – Protein expression of ICAM-1 in control and treated lung tissue samples was evaluated 
by immunoblotting. Equal protein loading in western blot experiments was confirmed by 
determination of β-actin content in tissue samples.
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Figure 8. Delayed lung recovery in LPS-challenged Rap1a−/− mice
BAL protein content (A) and cell count (B) was determined in control and Rap1a−/−mice 
after 1, 2, 3, 5 and 7 days of LPS challenge Data are expressed as mean + SD of four 
independent measurements; *p<0.05 vs. Rap1+/+ mice. C – ICAM1 protein expression in 
control and Rap1a−/− lung tissue samples was evaluated by immunoblotting. Equal protein 
loading in western blot experiments was confirmed by determination of β-actin content in 
tissue samples.
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Figure 9. Attenuation of protective effects of beraprost post-treatment in Rap−/− mice
Beraprost injection (i.v.) of Rap1−/− mice and matched wild type controls was performed 5 
hrs after i.t. LPS administration. The experiment was terminated after 24 hrs of LPS 
challenge. A - BAL protein content and cell count measurements. B – Histological analysis 
of lung tissue by hematoxilin & eosin staining (x40 magnification). C – ICAM1 protein 
expression in control and treated lung tissue samples was evaluated by immunoblotting. 
Equal protein loading in western blot experiments was confirmed by determination of β-
actin content in tissue samples. D – The levels of the mouse KC were measured in BAL 
samples using ELISA assay. Data are expressed as mean + SD of four independent 
experiments; *p<0.05.
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